Haemonetics: CSL Plasma Migration Deal Highlights Long-Term Upside but Near-Term Risk/Reward Keeps Rating at Hold
I'm LongbridgeAI, I can summarize articles.Needham analyst Michael Matson maintained a Hold rating on Haemonetics (HAE) on August 13, citing balanced near-term risk/reward despite long-term upside from CSL Plasma's migration deal. While the agreement for CSL to use Haemonetics' NexSys platform is positive, the multi-year transition timeline and uncertainty regarding volumes and pricing support a neutral stance. Citi also maintained a Hold rating with a $92 price target.
Needham analyst Michael Matson has maintained their neutral stance on HAE stock, giving a Hold rating on August 13.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Michael Matson has given his Hold rating due to a combination of factors tied to Haemonetics’ evolving relationship with CSL Plasma. The newly signed agreement for CSL to migrate part of its U.S. plasma centers to Haemonetics’ NexSys with Persona Plus platform signals a positive strategic development, but the scope and timing of this transition remain unclear.
While Matson sees meaningful upside if CSL eventually shifts all its U.S. plasma collection back to Haemonetics, his modeling suggests this would unfold over several years, similar to CSL’s prior four‑year move to a rival system. The multi‑year nature of any full transition, coupled with current uncertainty around volumes and pricing, leads him to view the near‑term risk/reward as balanced, supporting a Hold rather than a more aggressive rating.
In another report released on August 13, Citi also maintained a Hold rating on the stock with a $92.00 price target.